NDATOPICALSWAB
Approved
Feb 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
14
Data completeness
4/8 — Partial
ERYCETTE (erythromycin) by Johnson & Johnson is clinical pharmacology orally administered erythromycin base and its salts are readily absorbed in the microbiologically active form. Approved for acne vulgaris, pneumonia, blepharitis. First approved in 1985.
Drug data last refreshed Yesterday
Mechanism of Action
CLINICAL PHARMACOLOGY Orally administered erythromycin base and its salts are readily absorbed in the microbiologically active form. Interindividual variations in the absorption of erythromycin are, however, observed, and some patients do not achieve optimal serum levels. Erythromycin is largely…
Worked on ERYCETTE at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.